JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the underwriters for its previously announced offerings of its American Depositary Shares (“ADSs”), each representing one Teva ordinary share, and its 7.00% Mandatory Convertible Preferred Shares have exercised in full their option to purchase an additional 5,400,000 ADSs and 337,500 Mandatory Convertible Preferred Shares. As a result, Teva expects to receive an additional $658 million in net proceeds, for an aggregate of approximately $7.24 billion including the initial closing, in each case after estimated underwriting discounts, commissions and offering expenses payable by Teva. Closing of this additional sale is expected to occur on January 6, 2016.
